Related Experiment Video
Updated: Feb 19, 2026
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.3K
Ibrutinib-Associated Nail Plate Abnormalities: Case Reports and Review
Lucas A Heldt Manica1, Philip R Cohen2
1John A. Burns School of Medicine, University of Hawaii, 5737 Kalanianaole hwy, Honolulu, HI, 96821-1741, USA. manica@hawaii.edu.
Drug Safety - Case Reports
|November 3, 2017
Summary
Ibrutinib, a treatment for chronic lymphocytic leukemia (CLL), can cause nail plate abnormalities. These side effects are common but do not limit the drug
Area of Science:
- Oncology
- Dermatology
Background:
- Chronic lymphocytic leukemia (CLL) is a B-lymphocyte malignancy.
- Ibrutinib is an effective therapy for CLL.
- Cutaneous adverse events are associated with ibrutinib therapy.
Purpose of the Study:
- To describe nail plate abnormalities in CLL patients treated with ibrutinib.
- To review ibrutinib-associated nail abnormalities in CLL.
Main Methods:
- Case report of two CLL patients with nail abnormalities.
- Literature review using PubMed (keywords: abnormal, abnormalities, adverse, brittle, chronic, cutaneous, dystrophy, events, effects, ibrutinib, lymphocytic, leukemia, nail, plate, side).
Main Results:
- Two CLL patients developed nail plate abnormalities after ibrutinib initiation.
- Nail abnormalities are a common adverse event in patients receiving ibrutinib for CLL.
- Other reported side effects include bruising, hair changes, pruritus, and rashes.
Conclusions:
- Ibrutinib is a well-tolerated treatment for CLL.
- Nail plate abnormalities are a frequent adverse event but not drug-limiting.
- Monitoring for and managing nail changes may be necessary during ibrutinib therapy.
